Reaction
Induration reporting signals
As of the last recalculation, Induration appears in 1,759 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is FONDAPARINUX SODIUM (PRR 29.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Fondaparinux Sodium | 20 | 29.6 | 29.6 |
| Inclisiran | 19 | 28.3 | 28.4 |
| Cabotegravir | 10 | 14.7 | 14.7 |
| Iohexol | 9 | 12.9 | 12.9 |
| Octreotide Acetate | 30 | 11.8 | 11.8 |
| Infliximab-Dyyb | 27 | 11.1 | 11.1 |
| Daspone | 9 | 11.0 | 11.0 |
| Dapsone Gel, 5% | 9 | 11.0 | 11.0 |
| Epoetin Alfa | 10 | 10.0 | 10.0 |
| Dapsone | 9 | 10.0 | 10.0 |
| Abacavir Sulfate | 8 | 9.8 | 9.8 |
| Lanreotide Acetate | 6 | 9.1 | 9.1 |
| Alirocumab | 18 | 8.6 | 8.6 |
| Iron Sucrose | 6 | 7.5 | 7.5 |
| Aflibercept | 19 | 7.3 | 7.3 |
| Darunavir | 9 | 7.1 | 7.1 |
| Fremanezumab-Vfrm | 6 | 6.2 | 6.2 |
| Pegvaliase-Pqpz | 4 | 5.8 | 5.8 |
| Ado-Trastuzumab Emtansine | 4 | 5.6 | 5.6 |
| Cetuximab | 14 | 5.3 | 5.3 |
| Glatiramer Acetate | 22 | 4.4 | 4.4 |
| Interferon Beta-1A | 67 | 4.2 | 4.2 |
| Etanercept | 184 | 3.9 | 3.9 |
| Vemurafenib | 4 | 3.9 | 3.9 |
| Ixekizumab | 11 | 3.5 | 3.5 |
| Glycerin, Lidocaine | 3 | 2.5 | 2.5 |
| Docosanol | 3 | 2.4 | 2.4 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 5 | 1.9 | 1.9 |